Key result
CSL112 infusion post-MI significantly increases cholesterol efflux capacity and key HDL-associated proteins.
Why the study?
Does Apolipoprotein A1 (CSL112) infusion improve HDL protein composition, cholesterol esterification rate, and cholesterol efflux capacity in patients treated after acute myocardial infarction?
Does Apolipoprotein A1 (CSL112) infusion improve HDL protein composition, cholesterol esterification rate, and cholesterol efflux capacity in patients treated after acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
CSL112 infusion favorably alters HDL protein composition and promotes reverse cholesterol transport in patients following acute myocardial infarction.
Although high-density lipoprotein (HDL) cholesterol is inversely correlated with cardiovascular risk, an emerging paradigm is focused on increasing reverse cholesterol transport (RCT) and HDL function via apolipoprotein A1 (ApoA1). The objective of this study was to investigate the effect of ApoA1 (CSL112) infusion on HDL protein composition, cholesterol esterification rate (CER), and cholesterol efflux capacity (CEC) in patients treated after acute myocardial infarction. CSL112 reduced levels of apolipoproteins A2, B, C, and E and serum amyloids A1 and A4, whereas ApoA1, ApoM, and lecithin-cholesterol acyltransferase were significantly elevated. Increased CEC, plasma HDL cholesterol levels, CER, and CEC also were observed in CSL112-treated patients.
No takes yet. Share an insight, caveat, or question.
Velkoska et al. (2024) studied acute myocardial infarction. ApoA1 (CSL112) was evaluated on HDL protein composition, cholesterol esterification rate (CER), and cholesterol efflux capacity (CEC). ApoA1 (CSL112) infusion in post-myocardial infarction patients significantly elevated ApoA1, ApoM, and lecithin-cholesterol acyltransferase, and increased cholesterol efflux capacity.
Synapse has enriched 10 related papers. Consider them for comparative context: